David Andrew Shaywitz, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Product Surveillance, Postmarketing | 1 | 2019 | 430 | 0.500 |
Why?
|
| Biotechnology | 2 | 2007 | 278 | 0.490 |
Why?
|
| Research Personnel | 3 | 2007 | 573 | 0.450 |
Why?
|
| Drug Industry | 3 | 2007 | 744 | 0.430 |
Why?
|
| Information Dissemination | 1 | 2019 | 1100 | 0.370 |
Why?
|
| Gastroparesis | 2 | 2021 | 131 | 0.340 |
Why?
|
| Career Mobility | 2 | 2007 | 262 | 0.310 |
Why?
|
| Technology Transfer | 1 | 2007 | 44 | 0.300 |
Why?
|
| Entrepreneurship | 1 | 2005 | 24 | 0.270 |
Why?
|
| Growth and Development | 1 | 2005 | 51 | 0.260 |
Why?
|
| Spouses | 1 | 2006 | 284 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2007 | 3306 | 0.210 |
Why?
|
| Fungal Proteins | 2 | 1997 | 912 | 0.210 |
Why?
|
| Conflict of Interest | 1 | 2006 | 542 | 0.200 |
Why?
|
| Congresses as Topic | 1 | 2006 | 764 | 0.190 |
Why?
|
| Drug Discovery | 1 | 2009 | 1057 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 7901 | 0.160 |
Why?
|
| Coated Vesicles | 1 | 1997 | 24 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2217 | 0.150 |
Why?
|
| Periodicals as Topic | 3 | 2006 | 1431 | 0.150 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 1997 | 199 | 0.140 |
Why?
|
| Medical Errors | 1 | 2004 | 1296 | 0.140 |
Why?
|
| Medicine | 1 | 2004 | 941 | 0.140 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1581 | 0.140 |
Why?
|
| International Cooperation | 1 | 2002 | 1421 | 0.130 |
Why?
|
| Research | 2 | 2002 | 1999 | 0.130 |
Why?
|
| Physician's Role | 1 | 2002 | 942 | 0.130 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 390 | 0.120 |
Why?
|
| Industry | 2 | 2006 | 365 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 3617 | 0.110 |
Why?
|
| Developing Countries | 2 | 2002 | 2789 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 2 | 1997 | 1144 | 0.110 |
Why?
|
| Malaria | 1 | 2002 | 1232 | 0.110 |
Why?
|
| Education, Medical | 2 | 2002 | 1717 | 0.100 |
Why?
|
| Research Support as Topic | 2 | 2006 | 704 | 0.100 |
Why?
|
| Biology | 2 | 2005 | 292 | 0.100 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1997 | 1884 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2000 | 1436 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2002 | 1904 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 1997 | 7873 | 0.090 |
Why?
|
| Physicians | 1 | 2007 | 4554 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2007 | 11470 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 1997 | 2440 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 2 | 2009 | 1071 | 0.070 |
Why?
|
| Consultants | 1 | 2006 | 53 | 0.070 |
Why?
|
| Endoderm | 1 | 2007 | 150 | 0.070 |
Why?
|
| Utah | 1 | 2006 | 126 | 0.070 |
Why?
|
| Nuclear Pore Complex Proteins | 2 | 1997 | 165 | 0.060 |
Why?
|
| Publishing | 2 | 2002 | 833 | 0.060 |
Why?
|
| Happiness | 1 | 2006 | 170 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1997 | 5019 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 780 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2006 | 773 | 0.050 |
Why?
|
| GTP-Binding Proteins | 2 | 1997 | 970 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2006 | 451 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2001 | 127 | 0.050 |
Why?
|
| Disclosure | 1 | 2006 | 736 | 0.050 |
Why?
|
| Universities | 1 | 2005 | 953 | 0.050 |
Why?
|
| United States | 3 | 2019 | 69693 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 1294 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2021 | 233 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1997 | 2255 | 0.040 |
Why?
|
| COP-Coated Vesicles | 1 | 1997 | 41 | 0.040 |
Why?
|
| Science | 1 | 2000 | 241 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 2 | 1997 | 497 | 0.040 |
Why?
|
| HIV Infections | 1 | 2002 | 16678 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 1997 | 410 | 0.030 |
Why?
|
| World Health Organization | 1 | 2002 | 1317 | 0.030 |
Why?
|
| Humans | 11 | 2021 | 742088 | 0.030 |
Why?
|
| Specialization | 1 | 2000 | 777 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2000 | 725 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1997 | 2749 | 0.030 |
Why?
|
| Mentors | 1 | 2000 | 630 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 1503 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1995 | 319 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 1997 | 377 | 0.030 |
Why?
|
| Disease | 1 | 2000 | 681 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1995 | 561 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 402 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 2211 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 1994 | 321 | 0.030 |
Why?
|
| Program Development | 1 | 2000 | 1314 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 1402 | 0.030 |
Why?
|
| Binding Sites | 3 | 1997 | 6115 | 0.030 |
Why?
|
| Teaching | 1 | 2000 | 1174 | 0.030 |
Why?
|
| CHO Cells | 1 | 1995 | 1407 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1997 | 4013 | 0.030 |
Why?
|
| Cricetinae | 1 | 1995 | 2471 | 0.020 |
Why?
|
| Patient Participation | 1 | 2000 | 1445 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 12071 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 2505 | 0.020 |
Why?
|
| Biological Transport | 1 | 1995 | 2119 | 0.020 |
Why?
|
| Internet | 1 | 2002 | 3062 | 0.020 |
Why?
|
| Risk | 1 | 2001 | 9679 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 804 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1995 | 13814 | 0.020 |
Why?
|
| Pancreas | 1 | 1995 | 1684 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2000 | 2283 | 0.020 |
Why?
|
| Protein Binding | 2 | 1997 | 9387 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 1470 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 18112 | 0.020 |
Why?
|
| Curriculum | 1 | 2000 | 3589 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12017 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2000 | 3215 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2004 | 5304 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 139 | 0.020 |
Why?
|
| Antigens | 1 | 1992 | 1462 | 0.020 |
Why?
|
| Base Sequence | 2 | 1995 | 12797 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3770 | 0.020 |
Why?
|
| Multipotent Stem Cells | 1 | 2007 | 183 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 19223 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2000 | 4681 | 0.020 |
Why?
|
| Mesoderm | 1 | 2007 | 686 | 0.010 |
Why?
|
| Animals | 5 | 2007 | 168561 | 0.010 |
Why?
|
| Rats | 2 | 1995 | 24265 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 6096 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3920 | 0.010 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 1994 | 19 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1994 | 118 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1994 | 101 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1994 | 377 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 9735 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Mutation | 2 | 1995 | 29717 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1994 | 682 | 0.010 |
Why?
|
| Conalbumin | 1 | 1992 | 5 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 2837 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 1827 | 0.010 |
Why?
|
| Clone Cells | 1 | 1992 | 1692 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 213127 | 0.000 |
Why?
|
| Kinetics | 1 | 1994 | 6474 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 3133 | 0.000 |
Why?
|
| Ligands | 1 | 1992 | 3293 | 0.000 |
Why?
|
| Mice | 2 | 2007 | 81045 | 0.000 |
Why?
|
| Male | 1 | 2021 | 349538 | 0.000 |
Why?
|
| Female | 1 | 2021 | 379592 | 0.000 |
Why?
|